USPTO Examiner BROWE DAVID - Art Unit 1617

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18660885BLETILLA STRIATA POLYSACCHARIDE IRON COMPLEX, PREPARATION METHOD THEREFOR AND USE THEREOFMay 2024March 2025Abandon1011NoNo
18417945NOVEL FEAZD, NIAZD, AND CUAZD COMPLEXES INCORPORATING 1-(2-HYDROXYPHENYLAZO)-2-NAPHTHOL (H2AZD) FOR BIOLOGICAL APPLICATIONSJanuary 2024December 2024Allow1021YesNo
18417989NOVEL FEAZD, NIAZD, AND CUAZD COMPLEXES INCORPORATING 1-(2-HYDROXYPHENYLAZO)-2-NAPHTHOL (H2AZD) FOR BIOLOGICAL APPLICATIONSJanuary 2024May 2025Abandon1621NoNo
18523274PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIBNovember 2023April 2025Abandon1611NoNo
18387552PYRIDINO-2,16-DIOXAPENTACYCLO[7.7.5.01,21.03,8.010,15]HENICOSA3(8),10,12,14-TETRAENE-7,20-DIONE AS AN ANTIMICROBIAL COMPOUNDNovember 2023March 2024Allow401NoNo
18373774COMBINATION THERAPYSeptember 2023June 2025Abandon2101NoNo
18458973COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLSAugust 2023March 2024Allow711YesNo
18457738PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL 2 FAMILY INHIBITORAugust 2023June 2025Abandon2201NoNo
18233210NOVEL FEAZD, NIAZD, AND CUAZD COMPLEXES INCORPORATING 1-(2-HYDROXYPHENYLAZO)-2-NAPHTHOL (H2AZD) FOR BIOLOGICAL APPLICATIONSAugust 2023May 2025Abandon2141NoNo
18355684AMORPHOUS SOLID DISPERSION GANAXOLONE FORMULATIONJuly 2023December 2024Abandon1721NoNo
18330402Ciliated protozoan with the effect of promoting plant seed germination and seedling growthJune 2023March 2024Allow1020YesNo
18206290METHODS OF TREATING B-CELL PROLIFERATIVE DISORDERJune 2023September 2023Allow410YesNo
18203759METHODS OF TREATING B-CELL PROLIFERATIVE DISORDERMay 2023November 2023Allow510YesNo
18184228CONTROLLED-RELEASE AND STRATIFIED CYCLODEXTRIN INCLUSION COMPLEX VEHICLESMarch 2023December 2024Allow2211NoNo
18121826METHODS OF MANUFACTURE OF NUT FLOURS AND FORMULATIONS FOR ORAL IMMUNOTHERAPYMarch 2023April 2025Abandon2501NoNo
18173230THEAFLAVIN COMPOSITION CAPABLE OF PROMOTING WOUND HEALING AS WELL AS PREPARATION METHOD AND USE THEREOFFebruary 2023July 2024Abandon1721NoNo
18105285Methods of Administering Belumosudil for Treatment of Chronic Graft Versus Host DiseaseFebruary 2023May 2024Allow1521NoNo
18163041NANO-EMULSION OF CBF�-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVERFebruary 2023June 2025Allow2821NoNo
18098938METHODS OF TREATING B-CELL PROLIFERATIVE DISORDERJanuary 2023April 2023Allow301NoNo
18064767SUBLINGUAL FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID WITH CITRIC ACID, SODIUM BICARBONATE ,AND L-THEANINE FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTIONDecember 2022June 2025Abandon3011NoNo
18072747NOVEL KETOGENIC COMPOUNDS, COMPOSITIONS, METHODS AND USE THEREOFDecember 2022February 2025Allow2621NoNo
17977917SELF-PRESERVING TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING DIETHYLENE GLYCOL MONOETHYL ETHEROctober 2022January 2024Abandon1420YesNo
17973749PREPARATION OF SOLID CYCLODEXTRIN COMPLEXES FOR OPHTHALMIC ACTIVE PHARMACEUTICAL INGREDIENT DELIVERYOctober 2022November 2024Abandon2501NoNo
17893664COMPOSITION FOR CROP CARE AND PROTECTIONAugust 2022November 2024Abandon2601NoNo
17885105PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIBAugust 2022December 2023Abandon1721NoNo
17882014DRUG PRODUCTS FOR INTRANASAL ADMINISTRATION AND USES THEREOFAugust 2022March 2024Abandon2030YesNo
17866877PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIBJuly 2022May 2024Abandon2221YesYes
17758163FLOATING DRUG DELIVERY SYSTEMS COMPRISING CANNABINOIDSJune 2022June 2025Abandon3601NoNo
17850088COMPOSITIONS AND METHODS FOR TREATING EPILEPSY, SEIZURES AND OTHER CONDITIONSJune 2022August 2023Abandon1412NoNo
17824518PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIBMay 2022December 2023Abandon1931NoNo
17737929COMPOSITIONS AND METHODS FOR KELOIDLESS HEALINGMay 2022October 2024Abandon2901NoNo
17736386CONTROLLED-RELEASE AND STRATIFIED CYCLODEXTRIN INCLUSION COMPLEX VEHICLESMay 2022December 2022Allow811NoNo
17732080OIL-IN-WATER EMULSION OF MOMETASONEApril 2022January 2025Abandon3311NoNo
17731920DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATORApril 2022May 2025Abandon3711NoNo
17721909SURFACE-TREATING WOOD TO PREVENT DISCOLORATIONApril 2022June 2024Abandon2601NoNo
17713596THERAPEUTIC HYDROGELSApril 2022March 2025Allow3521NoNo
17703427GEL BASE COMPOSITION FOR COMPOUNDING INTO A MUCOADHESIVE DELIVERY SYSTEMMarch 2022December 2023Abandon2022YesNo
17578844METHODS AND COMPOSITIONS FOR USING CINNAMALDEHYDE AND ZINC FOR WEIGHT MANAGEMENTJanuary 2022December 2024Abandon3521NoNo
17645244PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL 2 FAMILY INHIBITORDecember 2021October 2022Abandon1001NoNo
17540965Inorganic Nitrite to Improve Cardiopulmonary HemodynamicsDecember 2021March 2024Allow2720YesNo
17521928COMPOSITION FOR IMPROVING SKIN CONDITIONSNovember 2021January 2024Abandon2710NoNo
17505902ANTIFUNGAL COMPOSITION HAVING EXCELLENT ANTIFUNGAL ACTIVITY EVEN AT LOW TEMPERATUREOctober 2021December 2024Allow3840NoNo
17604282ORAL DELIVERY SYSTEMS BASED ON IN SITU FORMING PROTEIN/POLYSACCHARIDE COACERVATESOctober 2021April 2023Allow1831YesNo
17501519TABLETS FOR ORAL SUSPENSION CONTAINING RIVAROXABANOctober 2021April 2025Abandon4231YesYes
17448450METHODS FOR TREATMENT OF POST-SURGERY LAXITY OF TENDONS AND TENDON REPAIRSeptember 2021June 2023Abandon2121YesNo
17480481METHODS AND APPARATUS FOR TREATING A WOUNDSeptember 2021January 2024Abandon2811NoNo
17475489SUSTAINED RELEASE BUPRENORPHINE MICROSPHERES (SRBM) AND METHODS OF USE THEREOFSeptember 2021November 2023Abandon2610NoNo
17471524NEW ALKYNYL-SUBSTITUTED 3-PHENYLPYRROLIDINE-2,4-DIONES AND USE THEREOF AS HERBICIDESSeptember 2021October 2023Abandon2501NoNo
17463369CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST AND METHODS OF MAKINGAugust 2021February 2024Abandon2931NoYes
17398960Cosmetic Skin Cream and MedicineAugust 2021June 2024Abandon3411NoNo
17388453CONTAINERIZED LIQUID FORMULATIONSJuly 2021July 2025Allow4731NoNo
17378041SOLID DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) COMPOSITIONSJuly 2021February 2023Abandon1931YesNo
17422448A METHOD OF MANUFACTURING A PHARMACEUTICAL COMPOSITION COMPRISING NEFOPAM AND ACETAMINOPHEN, AND THE PHARMACEUTICAL COMPOSITION OBTAINED THEREBYJuly 2021March 2025Abandon4451YesNo
17373711RADIATION SENSITIZER OR ANTI-CANCER CHEMOTHERAPY SENSITIZERJuly 2021February 2024Abandon3111NoNo
17372403INTRANASAL NANO INDUCER FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES AND METHOD THEREOFJuly 2021October 2024Abandon4021YesNo
16973000CHITOSAN GELS (A) CONTAINING METAL NANOPARTICLES OF COPPER, SILVER AND ANTIBIOTICS (CIPROFLOXACIN, CEFOTAXIME, GENTAMICIN AND CLOXACILLIN)July 2021August 2024Abandon4401NoNo
17357058Fulvic Acid Sterilization Deodorant As Well As Preparation Method and Application ThereofJune 2021December 2024Abandon4221NoNo
17342645SUSTAINED RELEASE COMPOSITIONS COMPRISING LIOTHYRONINEJune 2021December 2023Allow3061YesNo
17303736COMPOSITION AND METHOD TO PREVENT PATHOGEN TRANSMISSION THROUGH ALTERING SALIVAJune 2021May 2024Abandon3511NoNo
17331505METHODS OF ADMINISTERING ELAGOLIX IN ASSOCIATION WITH ARTIFICIAL REPRODUCTIVE TECHNOLOGIESMay 2021December 2022Abandon1921YesNo
17327702METHODS OF TREATING EYE DISEASE WITH TOBRAMYCIN-RELATED COMPOSITIONSMay 2021November 2022Allow1831YesNo
17302509Personal Care Composition with Zinc Phosphate ActiveMay 2021October 2024Abandon4121NoNo
17306442TOPICALLY-APPLIED PROBIOTIC TO TREAT DYSBIOSIS IN THE SKIN MICROBIOME OF PETS AND OTHER ANIMALSMay 2021November 2023Abandon3010NoNo
17224009USE OF CHROMIUM HISTIDINATE FOR TREATMENT OF CARDIOMETABOLIC DISORDERSApril 2021November 2023Abandon3101NoNo
17222703BIODEGRADABLE DRUG DELIVERY COMPOSITIONApril 2021September 2023Abandon3001NoNo
17190504FLAVONOIDS AND LINOLEIC ACID USES IN HYPERTENSIONMarch 2021October 2022Abandon2041YesNo
17190329INHIBITION OF SPONTANEOUS METASTASIS VIA PROTEIN INHIBITORS OF CYSTEINE PROTEASESMarch 2021September 2023Abandon3001NoNo
17186439SUBLINGUAL APOMORPHINEFebruary 2021December 2023Abandon3301NoNo
17167428METHOD OF TREATING A DISEASE USING A GLYCOLYTIC DEPENDENT COMPOUNDFebruary 2021January 2024Allow3530NoNo
17167703SAFENED HERBICIDAL COMPOSITIONS CONTAINING HALAUXIFEN AND METHODS OF USE THEREOF IN BRASSICA SPECIESFebruary 2021January 2025Abandon4731NoNo
17156053PACKAGED MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED STABILITYJanuary 2021April 2024Abandon3811NoNo
17251440NOVEL KETOGENIC COMPOUNDS, COMPOSITIONS, METHODS AND USE THEREOFDecember 2020January 2023Abandon2621NoNo
17113908COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF EYELID SWELLINGDecember 2020October 2023Abandon3410NoNo
17112742PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL 2 FAMILY INHIBITORDecember 2020September 2023Abandon3301NoNo
16949756Aluminum-Free Antiperspirant / Deodorant CompositionsNovember 2020July 2023Abandon3231NoNo
17091489CELLULOSE NANOCRYSTAL-BASED EMULSIONS AND USES THEREOFNovember 2020October 2024Abandon4721YesNo
17086502GLASS STRUCTURE AND METHOD FOR PRODUCING THE SAMENovember 2020August 2024Abandon4521NoNo
17073326SURFACES COMPRISING ATTACHED QUORUM SENSING MODULATORSOctober 2020April 2025Abandon5431NoNo
17046538USE OF A NEW COMPOSITION FOR PREVENTING OR SLOWING THE APPEARANCE OF SIGNS OF INFLAMMATIONOctober 2020May 2025Allow5521NoNo
17030519SYNTHETIC PLATELETSSeptember 2020August 2024Abandon4621NoNo
17016528METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATINGSeptember 2020July 2024Allow4661NoYes
16979487Method of Treating Ciliated Tissue Using CSA MicellesSeptember 2020April 2024Allow4341NoNo
17002266METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATINGAugust 2020August 2024Abandon4831NoNo
16997983METHODS FOR SEQUESTERING CARBON OF ORGANIC MATERIALSAugust 2020January 2022Abandon1721NoNo
16995362Compositions, Methods and/or Devices for Prevention and/or Treatment of Dry Eye DisordersAugust 2020October 2024Abandon5051YesNo
16969292Pharmaceutical Composition of BrigatinibAugust 2020August 2023Abandon3611NoNo
16989295COMBINATION FORMULATION CONTAINING SUSTAINED RELEASE METFORMIN AND IMMEDIATE RELEASE HMG-COA REDUCTASE INHIBITORAugust 2020March 2023Abandon3101NoNo
16967533GAMMA POLYGLUTAMATED AMINOPTERIN AND USES THEREOFAugust 2020March 2025Allow5521NoNo
16984645PACKAGED MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED STABILITYAugust 2020April 2023Abandon3251YesYes
16967265N-ACETYLCYSTEINE AND UREA-BASED FORMULATION FOR THE TREATMENT OF DERMATOLOGICAL DISORDERSAugust 2020November 2024Abandon5141NoNo
16945040AMINO ACID FORMULATIONS AND USES THEREOFJuly 2020March 2025Abandon5541YesYes
16966869ANTICANCER MICRORNA AND LIPID FORMULATIONS THEREOFJuly 2020March 2024Abandon4401NoNo
16940787Formulations And Methods For Treating Photosynthetic Organisms And Enhancing Qualities And Quantities Of Yields With Glycan Composite FormulationsJuly 2020December 2023Allow4120NoNo
16940784Formulations And Methods For Treating Photosynthetic Organisms And Enhancing Qualities And Quantities Of Yields With Glycan Composite FormulationsJuly 2020February 2025Allow5570YesNo
16936678COMPOSITION OF PICKERING EMULSION COMPRISING LOW AMOUNT OF ALCOHOLJuly 2020April 2025Abandon5681YesNo
16935918SILICONE AND SILOXANE-BASED IMPREGNATED COATING AND POLYMERIC MATERIALS FOR CONDITIONINGJuly 2020November 2024Allow5121NoYes
16963532A BASE AND PHARMACEUTICAL COMPOSITION CONTAINING ITJuly 2020October 2024Allow5131YesNo
16921965METHOD FOR ENCOURAGING BUDDING FROM GROWING POINT OF PLANT, FOR INHIBITING APICAL BUD GROWTH, AND FOR INCREASING NUMBER OF LATERAL SHOOTS, AND SUBSTANCES MADE BY AND USED IN THE METHODJuly 2020July 2023Abandon3601NoNo
16959357ORAL PHARMACEUTICAL FORMULATION COMPRISING CANNABINOIDS AND POLOXAMERJune 2020May 2024Abandon4631NoNo
16958897EMULSIFIED COMPOSITIONJune 2020December 2022Abandon3030YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BROWE, DAVID.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
65
Examiner Affirmed
39
(60.0%)
Examiner Reversed
26
(40.0%)
Reversal Percentile
60.0%
Higher than average

What This Means

With a 40.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
186
Allowed After Appeal Filing
41
(22.0%)
Not Allowed After Appeal Filing
145
(78.0%)
Filing Benefit Percentile
26.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 22.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner BROWE, DAVID - Prosecution Strategy Guide

Executive Summary

Examiner BROWE, DAVID works in Art Unit 1617 and has examined 767 patent applications in our dataset. With an allowance rate of 22.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.

Allowance Patterns

Examiner BROWE, DAVID's allowance rate of 22.4% places them in the 1% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BROWE, DAVID receive 3.12 office actions before reaching final disposition. This places the examiner in the 96% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BROWE, DAVID is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +30.0% benefit to allowance rate for applications examined by BROWE, DAVID. This interview benefit is in the 81% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 5.6% of applications are subsequently allowed. This success rate is in the 1% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 17.4% of cases where such amendments are filed. This entry rate is in the 13% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 19.6% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 25% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 44.4% of appeals filed. This is in the 7% percentile among all examiners. Of these withdrawals, 25.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 60.2% are granted (fully or in part). This grant rate is in the 77% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 57% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.